Aduro shows survival benefit with pancreatic cancer vaccine duo
This article was originally published in Scrip
Private US biotech company Aduro BioTech has reported a survival benefit in metastatic pancreatic cancer with its combination immunotherapy-based treatment, in a Phase II trial that was stopped early on the strength of the data after a pre-planned interim analysis.
You may also be interested in...
Doesn't every biopharma company have an immuno-oncology strategy these days? It certainly seems that way, considering the number of drug developers that are labeling their therapeutic candidates as immunotherapies regardless of whether the description truly fits their asset.
Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.